Center for Clinical and Basic Research AS
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At Center for Clinical and Basic Research AS in Tallin, a major focus is cardiovascular diseases, especially atherosclerotic cardiovascular disease and adults at high risk of heart attacks or stroke. These studies aim to evaluate whether new treatments can better reduce major heart-related events and improve protection for people receiving standard lipid-lowering care.
- Reducing the risk of coronary heart disease death, myocardial infarction, and ischemic stroke
- Testing treatment effectiveness in high-risk patients without prior heart attack or stroke
- Assessing cardiovascular outcomes in people with chronic kidney disease and related risk factors
This work reflects a strong clinical interest in preventing serious cardiovascular events through better long-term disease management and outcome-focused research.
Respiratory and Infectious Disease Studies
The site also conducts research in respiratory tract diseases and virus diseases, with trials centered on influenza, respiratory syncytial virus, human metapneumovirus, and cytomegalovirus infection. The main goal is to test vaccines that may improve prevention, immune response, and protection against seasonal and serious viral infections.
- Evaluating influenza vaccine safety, immune response, and protection in older adults
- Studying RSV and hMPV vaccine effectiveness for preventing lower respiratory tract disease
- Investigating a vaccine candidate to prevent primary CMV infection
These trials support efforts to strengthen infection prevention, particularly in older adults and other groups who may be more vulnerable to respiratory illness.
Autoimmune and Inflammatory Disease Research
Another important area at the Cardiology department is immune system diseases, including primary Sjögren’s disease, plaque psoriasis, and psoriatic arthritis. The research is designed to assess whether new therapies can better control symptoms, reduce disease activity, and improve quality of life for people living with chronic inflammatory conditions.
- Measuring disease activity in primary Sjögren’s disease
- Testing treatment effectiveness for moderate to severe plaque psoriasis
- Evaluating symptom control and response in psoriatic arthritis
This portfolio highlights a clear interest in advancing more targeted options for autoimmune and inflammatory disorders.
Bone, Joint, and Metabolic Health Research
The site’s musculoskeletal diseases and nutritional and metabolic diseases research includes osteoarthritis, postmenopausal osteoporosis, and broader bone health concerns. These trials are focused on improving joint structure, increasing bone density, and exploring therapies that may help slow disease progression or strengthen skeletal health.
- Assessing changes in knee structure in osteoarthritis
- Evaluating treatment effects on bone mineral density in postmenopausal women
- Exploring new approaches to support long-term musculoskeletal health
The research combines symptom-focused care with efforts to address underlying structural and metabolic aspects of these conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Center for Clinical and Basic Research AS
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study | Amgen Inc. | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) | 3 | Unknown | 2023-11-03 | 2025-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.